Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU recommends framework for patient safety with focus on healthcare-associated infections

This article was originally published in SRA

Executive Summary

The European Commission has adopted a communication and a proposal for a council recommendation to improve patient safety in the European Union that encourages member states to collectively address areas of concern, including healthcare-associated infections, medical equipment-related failures and medication errors1-4. The decision has been prompted by data showing that around 8% to 12% of patients admitted to hospital experience adverse events while receiving healthcare.

You may also be interested in...



Switzerland Fast Tracks Registration Of EU/US-Approved Anti-Infectives

Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.

EU Makes ISO Format Mandatory For Side-Effect Reporting From June 2022

Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.

UK Heads For Full Trial Transparency

The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.

UsernamePublicRestriction

Register

MT038456

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel